Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.57 |
| ▸ | ANPEP | P15144 | 3/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337622 | 0.79 | LAP3 (0.61) | LAP3ANPEPERAP2ENPEP | |
| SCHEMBL5034289 | 0.78 | ECE1 (0.53) | — | |
| SCHEMBL2600694 | 0.77 | ALDH1A1 (0.60) | ANPEP | |
| SCHEMBL517463 | 0.77 | ALDH1A1 (0.60) | ANPEP | |
| SCHEMBL17761604 | 0.77 | ALDH1A1 (0.60) | ANPEP | |
| Phenylalanine Methyl Ester SCHEMBL9355493 | 0.77 | LAP3 (0.58) | LAP3ANPEP | |
| Phenylalanine Methyl Ester SCHEMBL9355479 | 0.77 | LAP3 (0.58) | LAP3ANPEP | |
| Ammonia Solution, Strong SCHEMBL9995407 | 0.76 | ALDH1A1 (0.59) | ANPEP | |
| SCHEMBL1531741 | 0.76 | ALDH1A1 (0.52) | ANPEP | |
| SCHEMBL13386099 | 0.76 | ALDH1A1 (0.52) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1685142-A1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044830-A1 | PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | LAP3 389/4885ANPEP 335/4885ERAP2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.